Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.

ABSTRACT:

SUBMITTER: Maiti A 

PROVIDER: S-EPMC5250544 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature